NO981708L - FremgangsmÕte for deteksjon av cyklooksygenase-2 - Google Patents

FremgangsmÕte for deteksjon av cyklooksygenase-2

Info

Publication number
NO981708L
NO981708L NO981708A NO981708A NO981708L NO 981708 L NO981708 L NO 981708L NO 981708 A NO981708 A NO 981708A NO 981708 A NO981708 A NO 981708A NO 981708 L NO981708 L NO 981708L
Authority
NO
Norway
Prior art keywords
cyclooxygenase
detection
Prior art date
Application number
NO981708A
Other languages
English (en)
Other versions
NO981708D0 (no
Inventor
Peter C Isakson
Karen Seibert
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO981708D0 publication Critical patent/NO981708D0/no
Publication of NO981708L publication Critical patent/NO981708L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO981708A 1995-10-17 1998-04-16 FremgangsmÕte for deteksjon av cyklooksygenase-2 NO981708L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US568695P 1995-10-17 1995-10-17
PCT/US1996/016440 WO1997014679A2 (en) 1995-10-17 1996-10-16 Method of detecting cyclooxygenase-2

Publications (2)

Publication Number Publication Date
NO981708D0 NO981708D0 (no) 1998-04-16
NO981708L true NO981708L (no) 1998-06-10

Family

ID=21717184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981708A NO981708L (no) 1995-10-17 1998-04-16 FremgangsmÕte for deteksjon av cyklooksygenase-2

Country Status (10)

Country Link
US (2) US6045773A (no)
EP (1) EP0859642A2 (no)
JP (1) JP2000510816A (no)
KR (1) KR19990064310A (no)
AU (1) AU716582B2 (no)
BR (1) BR9611047A (no)
CA (1) CA2234633A1 (no)
NO (1) NO981708L (no)
NZ (1) NZ322674A (no)
WO (1) WO1997014679A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
WO2002012445A1 (en) 2000-08-07 2002-02-14 Vanderbilt University Detection of cox-2 activity and anandamide metabolites
CN101444496B (zh) * 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
MXPA04003451A (es) 2001-10-09 2005-02-17 Dimensional Pharm Inc Difeniloxazoles substituidos, la sintesis de los mismos y el uso de los mismo como detectores fluorescencia.
DE60233742D1 (de) 2001-10-10 2009-10-29 Hitachi High Tech Corp Leuchtverbindungen und markierungsreagentien für die diese verwendet werden
US7329401B2 (en) 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
US7314709B2 (en) * 2002-08-06 2008-01-01 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
WO2004028338A2 (en) * 2002-09-27 2004-04-08 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
WO2005002293A2 (en) * 2003-06-25 2005-01-06 Vanderbilt University Cox-2-targeted imaging agents
US7112601B2 (en) * 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
WO2005095349A1 (en) * 2004-04-01 2005-10-13 Pharmacia & Upjohn Company Llc Crystalline pyrazole derivative
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
CA2562783A1 (en) * 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
KR20070100269A (ko) * 2005-01-04 2007-10-10 노파르티스 아게 인간 ｆｐｐｓ의 ｘ-선 구조 및 ｆｐｐｓ 결합 화합물의선별을 위한 용도
MX2007009888A (es) 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
US8303935B2 (en) * 2006-05-19 2012-11-06 Nihon Medi-Physics Co., Ltd. Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid
WO2007149456A2 (en) * 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
WO2007148755A1 (ja) * 2006-06-21 2007-12-27 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
US20090252680A1 (en) * 2006-11-17 2009-10-08 Nihon- Medi-Physics Co., Ltd Novel compound with affinity for amyloid
CA2670436A1 (en) * 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
PT2106808T (pt) * 2006-12-21 2018-03-26 Nihon Mediphysics Co Ltd Agente de imagiologia de diagnóstico radioativo compreendendo ácido 1-amino-3-[18f]fluoro-ciclobutanocarboxílico
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
JP5258583B2 (ja) 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
MX2010000465A (es) 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
KR20100091965A (ko) * 2007-10-24 2010-08-19 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
EP2216052A4 (en) * 2007-10-30 2012-11-21 Nihon Mediphysics Co Ltd USE OF A NEW COMPOUND WITH AFFINITY FOR AMYLOID AND METHOD FOR THE PRODUCTION THEREOF
WO2009057576A1 (ja) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物の使用及び製造方法
FR2926079B1 (fr) 2008-01-03 2012-12-28 Commissariat Energie Atomique Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations
EP2247558B2 (en) 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
JP2011529086A (ja) 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ａｄ病変を同定するために有用な造影剤
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
WO2019235824A1 (ko) * 2018-06-08 2019-12-12 경북대학교 산학협력단 Cox2 과발현 질환 진단용 조성물 및 이의 스크리닝 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (en) * 1993-01-15 1997-11-19 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en) * 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1995005395A1 (en) * 1993-08-17 1995-02-23 Fujisawa Pharmaceutical Co., Ltd. Method of diagnosing alzheimer's disease
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DE69422306T4 (de) * 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5459239A (en) * 1994-01-24 1995-10-17 Merck Frosst Canada Inc. Peptide sequences and antipeptide antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 proteins
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
BR9611047A (pt) 2000-03-08
CA2234633A1 (en) 1997-04-24
WO1997014679A3 (en) 1997-08-14
NO981708D0 (no) 1998-04-16
KR19990064310A (ko) 1999-07-26
JP2000510816A (ja) 2000-08-22
US6045773A (en) 2000-04-04
NZ322674A (en) 1999-08-30
AU716582B2 (en) 2000-03-02
WO1997014679A2 (en) 1997-04-24
AU7662996A (en) 1997-05-07
EP0859642A2 (en) 1998-08-26
US20010055565A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
NO981708D0 (no) FremgangsmÕte for deteksjon av cyklooksygenase-2
NO960059L (no) Fremgangsmåte for behandling av en underjordisk formasjon
NO973635D0 (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO962230L (no) Fremgangsmåte for bestemmelse av fluiders egenskaper
NO964051D0 (no) System for tidlig evaluering av en brönn
FI953445L (fi) Menetelmä nukleiinihappojen herkkään osoitukseen
FI955619L (fi) Menetelmä nukleiinihappojen erityisen herkäksi detektoimiseksi
BR9611130A (pt) Derivados de 3-aril-5-halógeno-pirona
NO961966L (no) Fremgangsmåte for korrigering av avviksregistrering
NO964479L (no) Fremgangsmåte for signalbehandling
DE69624211D1 (de) Signalverarbeitungsverfahren
DE19531845B4 (de) Verbrennungsaussetzererkennungsverfahren
FI951472L (fi) Radiometri ja menetelmä veden ilmaisemiseksi
DK0810923T3 (da) Fremgangsmåde til trykning
NO943532D0 (no) Fremgangsmåte for måling av vannhastighet
NO944736D0 (no) Fremgangsmåte for bestemmelse av blodhastighet
NO964084D0 (no) Påvisning av analytter
NO975699L (no) Fremgangsmåte for oksyklorering
FI973418L (fi) Vasta-ainetuotannon toteaminen
BR9607046A (pt) Derivados de 3-pirrolidiliden-2-ona-cefalosporinas
NO954829L (no) Fremgangsmåte for representasjon av seismisk informasjon
NO971753L (no) Fremgangsmåte for selektiv fraskillelse av morfolin
NO964083D0 (no) Påvisning av analytter
NO973926D0 (no) Deteksjon av biomolekyler
NO960391D0 (no) Fremgangsmåte for utvinning av fiskemel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application